|
1
|
Schermuly RT, Ghofrani HA, Wilkins MR and
Grimminger F: Mechanisms of disease: Pulmonary arterial
hypertension. Nat Rev Cardiol. 8:443–455. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baptista R, Meireles J, Agapito A, Castro
G, da Silva AM, Shiang T, Gonçalves F, Robalo-Martins S,
Nunes-Diogo A and Reis A: Pulmonary hypertension in Portugal: First
data from a nationwide registry. Biomed Res Int. 2013:4895742013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Humbert M, Gerry Coghlan J and Khanna D:
Early detection and management of pulmonary arterial hypertension.
Eur Respir Rev. 21:306–312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Helan M, Aravamudan B, Hartman WR,
Thompson MA, Johnson BD, Pabelick CM and Prakash YS: BDNF secretion
by human pulmonary artery endothelial cells in response to hypoxia.
J Mol Cell Cardiol. 68:89–97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bi R, Bao C, Jiang L, Liu H, Yang Y, Mei J
and Ding F: MicroRNA-27b plays a role in pulmonary arterial
hypertension by modulating peroxisome proliferator-activated
receptor gamma dependent Hsp90-eNOS signaling and nitric oxide
production. Biochem Biophys Res Commun. 460:469–475. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu Y, Liu G, Zhang H and Wang J:
MiRNA-199a-5p influences pulmonary artery hypertension via
downregulating Smad3. Biochem Biophys Res Commun. 473:859–866.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Caruso P, MacLean MR, Khanin R, McClure J,
Soon E, Southgate M, MacDonald RA, Greig JA, Robertson KE, Masson
R, et al: Dynamic changes in lung microRNA profiles during the
development of pulmonary hypertension due to chronic hypoxia and
monocrotaline. Arterioscler Thromb Vasc Biol. 30:716–723. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rothman AM, Chico TJ and Lawrie A:
MicroRNA in pulmonary vascular disease. Prog Mol Biol Transl Sci.
124:43–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wei W, Yang Y, Cai J, Cui K, Li RX, Wang
H, Shang X and Wei D: MiR-30a-5p suppresses tumor metastasis of
human colorectal cancer by targeting ITGB3. Cell Physiol Biochem.
39:1165–1176. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schultz NA and Johansen JS: YKL-40-A
protein in the field of translational medicine: A role as a
biomarker in cancer patients? Cancers (Basel). 2:1453–1491. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pouyafar A, Heydarabad MZ, Mahboob S,
Mokhtarzadeh A and Rahbarghazi R: Angiogenic potential of YKL-40 in
the dynamics of tumor niche. Biomed Pharmacother. 100:478–485.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun L, Wang D, Li H, et al: Significance
of high YKL-40 expression regulated by mir-24 in cervical cancer
progression and prognosis. Int J Clin Exp Pathol. 9:5128–5137.
2016.(In Chinese).
|
|
14
|
Rathcke CN and Vestergaard H: YKL-40-an
emerging biomarker in cardiovascular disease and diabetes.
Cardiovasc Diabetol. 8:612009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kastrup J: Can YKL-40 be a new
inflammatory biomarker in cardiovascular disease? Immunobiology.
217:483–491. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nojgaard C, Host NB, Christensen IJ,
Poulsen SH, Egstrup K, Price PA and Johansen JS: Serum levels of
YKL-40 increases in patients with acute myocardial infarction.
Coron Artery Dis. 19:257–263. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen G, Yang T, Gu Q, Ni XH, Zhao ZH, Ye
J, Meng XM, Liu ZH, He JG and Xiong CM: Elevated plasma YKL-40 as a
prognostic indicator in patients with idiopathic pulmonary arterial
hypertension. Respirology. 19:608–615. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Green DE, Murphy TC, Kang BY, Kleinhenz
JM, Szyndralewiez C, Page P, Sutliff RL and Hart CM: The Nox4
inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular
cell proliferation. Am J Respir Cell Mol Biol. 47:718–726. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yuan T, Chen Y, Zhang H, Fang L and Du G:
Salvianolic Acid A, a component of salvia miltiorrhiza, attenuates
endothelial-mesenchymal transition of HPAECs Induced by Hypoxia. Am
J Chin Med. 45:1185–1200. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bienertova-Vasku J, Novak J and Vasku A:
MicroRNAs in pulmonary arterial hypertension: Pathogenesis,
diagnosis and treatment. J Am Soc Hypertens. 9:221–234. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nie X, Chen Y, Tan J, Dai Y, Mao W, Qin G,
Ye S, Sun J, Yang Z and Chen J: MicroRNA-221-3p promotes pulmonary
artery smooth muscle cells proliferation by targeting AXIN2 during
pulmonary arterial hypertension. Vascul Pharmacol. 116:24–35. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Courboulin A, Paulin R, Giguere NJ,
Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher
S, Côté J, et al: Role for miR-204 in human pulmonary arterial
hypertension. J Exp Med. 208:535–548. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Baraniskin A, Birkenkamp-Demtroder K,
Maghnouj A, Zöllner H, Munding J, Klein-Scory S, Reinacher-Schick
A, Schwarte-Waldhoff I, Schmiegel W and Hahn SA: MiR-30a-5p
suppresses tumor growth in colon carcinoma by targeting DTL.
Carcinogenesis. 33:732–739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Y, Zhou Y, Gong X and Zhang C:
MicroRNA-30a-5p inhibits the proliferation and invasion of gastric
cancer cells by targeting insulin-like growth factor 1 receptor.
Exp Ther Med. 14:173–180. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen A, Liu J, Zhu J, Wang X, Xu Z, Cui Z,
Yao D, Huang Z, Xu M, Chen M, et al: FGF21 attenuates
hypoxiainduced dysfunction and apoptosis in HPAECs through
alleviating endoplasmic reticulum stress. Int J Mol Med.
42:1684–1694. 2018.PubMed/NCBI
|
|
27
|
Yu H, Liu J, Dong Y, Xu M, Xu L, Guan H,
Xia X and Wang L: Anti-hypoxic effect of dihydroartemisinin on
pulmonary artery endothelial cells. Biochem Biophys Res Commun.
506:840–846. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu W and Erzurum SC: Endothelial cell
energy metabolism, proliferation, and apoptosis in pulmonary
hypertension. Compr Physiol. 1:357–372. 2011.PubMed/NCBI
|
|
29
|
Fang F, Chang RM, Yu L, Lei X, Xiao S,
Yang H and Yang LY: MicroRNA-188-5p suppresses tumor cell
proliferation and metastasis by directly targeting FGF5 in
hepatocellular carcinoma. J Hepatol. 63:874–885. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Karalilova R, Kazakova M, Batalov A and
Sarafian V: Correlation between protein YKL-40 and ultrasonographic
findings in active knee osteoarthritis. Med Ultrason. 1:57–63.
2018. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tong X, Wang D, Liu S, Ma Y, Li Z, Tian P
and Fan H: The YKL-40 protein is a potential biomarker for COPD: A
meta-analysis and systematic review. Int J Chron Obstruct Pulmon
Dis. 13:409–418. 2018. View Article : Google Scholar : PubMed/NCBI
|
